17th St.Gallen International Breast Cancer Conference - BCC 2021

congress program
Location : Online
Country : Swiss
Language : ENG
Start :
End :
https://www.oncoconferences.ch/events/bcc-2021/
Specialities : Oncology
St. Gallen international consensus on the optimal primary treatment of women with breast cancer

- Date : 2021-03-21
- 1
0
Omitting axillary lymph node dissection in breast cancer patients after neoadjuvant chemotherapy

- Date : 2021-03-21
- 0
0
Safety outcomes in the Phase III monarchE trial of abemaciclib + ET in HR+, HER2- breast cancer

- Date : 2021-03-21
- 0
0
St. Gallen Consensus 2021: neoadjuvant and adjuvant therapy for HER2+ breast cancer

- Date : 2021-03-21
- 0
0
Circulating tumor cell count-driven vs clinician-driven 1L therapy in HR+, HER2- breast cancer

- Date : 2021-03-21
- 0
0
Will genomic profiling replace clinical and pathological risk factors in ER+ breast cancer?

- Date : 2021-03-21
- 0
0
Assessing the global impact of the COVID-19 pandemic on patients receiving breast cancer care

- Date : 2021-04-21
- 0
0
Prognostication using germline risk variants and RNA expression for breast cancer

- Date : 2021-03-21
- 0
0
St. Gallen Consensus highlights: ovarian suppression, oligometastatic disease and radiotherapy

- Date : 2021-03-21
- 0
0
Should chemotherapy be used in post-menopausal patients with low genomic risk HR+ breast cancer?

- Date : 2021-03-21
- 0
0
APHINITY: 6-year follow-up results of dual HER2 blockade in HER2+ breast cancer

- Date : 2021-03-21
- 0
0
EUROPA: endocrine therapy or partial breast irradiation for older women with breast cancer

- Date : 2021-03-21
- 0
0
Prescribing practices of endocrine therapy for premenopausal breast cancer patients in Mexico

- Date : 2021-03-21
- 0
0
HER2CLIMB: tucatinib efficacious against brain metastases in patients with HER2+ breast cancer

- Date : 2021-03-21
- 0
0
Genomic predictors for treatment selection in ER+ breast cancer: TAILORx, MINDACT, and RxPONDER

- Date : 2021-03-21
- 0
0
Real-world outcomes of HER2+ and TNBC patients recieving neoadjuvant chemotherapy

- Date : 2021-03-21
- 0
0
Mathematical modelling to predict recurrence periods for secondary metastases in breast cancer

- Date : 2021-03-21
- 0
0
CDK4/6 inhibitors in ER+ metastatic breast cancer during the COVID-19 pandemic

- Date : 2021-03-21
- 0
0
Systemic therapy at the St Gallen Consensus: multi-gene testing, Ki67, and oligometastatic disease

- Date : 2021-03-21
- 0
0
Phase III trial of denosumab for breast cancer risk reduction in BRCA1 carriers

- Date : 2021-03-21
- 0
0
Role of SPECT/CT in detecting marked lymph nodes and sentinel nodes following neoadjuvant chemo

- Date : 2021-03-21
- 0
0